Study identifier:1839IL/0050
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Expanded Access Clinical Program with ZD1839 (IRESSA®) for Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Carcinoma
Phase 3
No
ZD1839 (Gefitinib)
All
-
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: None
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2013 by AstraZeneca
AstraZeneca
-
A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.
Location
Location
Anchorage, AK, United States
Location
Fairbanks, AK, United States
Location
Alabaster, AL, United States
Location
Anniston, AL, United States
Location
Birmingham, AL, United States
Location
Gadsen, AL, United States
Location
Huntsville, AL, United States
Location
Montgomery, AL, United States
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.